OBJECTIVES: To determine the safety of the candidate vaginal microbicide SPL7013 gel (VivaGel) when applied to the penis. METHODS: A randomized, double-blind, placebo-controlled study. Thirty-six healthy men (18 circumcised, 18 uncircumcised) were randomized in a 2:1 ratio and treated with 3% SPL7013 gel (n = 24) or placebo gel (n = 12), applied once daily for 7 days. Genital toxicity was determined by interview, diary, and examination. RESULTS: There were 10 genital adverse events (AEs) in 6 men (25%) receiving SPL7013 gel and 5 genital AEs in 4 men (33%) receiving the placebo that were possibly or probably related to the study product (difference of -8%, 95% confidence interval: -40% to 23%, P = 0.70). The most common genital AEs were genital pruritus and application site erythema. All genital AEs were mild (grade 1), and all but 1 in the placebo group were transient. Analysis of vital signs, nongenital AEs, and laboratory results indicated no safety or tolerability issues with SPL7013 gel, irrespective of circumcision status. There was no detectable absorption of SPL7013 into the plasma. CONCLUSIONS: Three percent SPL7013 gel was safe and well tolerated, and comparable with placebo, when administered to the penis of both circumcised and uncircumcised men once daily for 7 days, with no evidence of systemic absorption or toxicity.
RCT Entities:
OBJECTIVES: To determine the safety of the candidate vaginal microbicide SPL7013 gel (VivaGel) when applied to the penis. METHODS: A randomized, double-blind, placebo-controlled study. Thirty-six healthy men (18 circumcised, 18 uncircumcised) were randomized in a 2:1 ratio and treated with 3% SPL7013 gel (n = 24) or placebo gel (n = 12), applied once daily for 7 days. Genital toxicity was determined by interview, diary, and examination. RESULTS: There were 10 genital adverse events (AEs) in 6 men (25%) receiving SPL7013 gel and 5 genital AEs in 4 men (33%) receiving the placebo that were possibly or probably related to the study product (difference of -8%, 95% confidence interval: -40% to 23%, P = 0.70). The most common genital AEs were genital pruritus and application site erythema. All genital AEs were mild (grade 1), and all but 1 in the placebo group were transient. Analysis of vital signs, nongenital AEs, and laboratory results indicated no safety or tolerability issues with SPL7013 gel, irrespective of circumcision status. There was no detectable absorption of SPL7013 into the plasma. CONCLUSIONS: Three percent SPL7013 gel was safe and well tolerated, and comparable with placebo, when administered to the penis of both circumcised and uncircumcised men once daily for 7 days, with no evidence of systemic absorption or toxicity.
Authors: Tom D McCarthy; Peter Karellas; Scott A Henderson; Michael Giannis; David F O'Keefe; Graham Heery; Jeremy R A Paull; Barry R Matthews; George Holan Journal: Mol Pharm Date: 2005 Jul-Aug Impact factor: 4.939
Authors: Sheila R Abner; Patricia C Guenthner; Jeannette Guarner; Kelly A Hancock; James E Cummins; Aaron Fink; G Thomas Gilmore; Charles Staley; Albert Ward; Odessa Ali; Sander Binderow; Stephen Cohen; Lisa A Grohskopf; Lynn Paxton; Clyde E Hart; Charlene S Dezzutti Journal: J Infect Dis Date: 2005-09-26 Impact factor: 5.226
Authors: Yong-Hou Jiang; Peter Emau; J Scott Cairns; Leon Flanary; William R Morton; Tom D McCarthy; Che-Chung Tsai Journal: AIDS Res Hum Retroviruses Date: 2005-03 Impact factor: 2.205
Authors: Edwin Gong; Barry Matthews; Tom McCarthy; Jianhua Chu; George Holan; John Raff; Stephen Sacks Journal: Antiviral Res Date: 2005-09-27 Impact factor: 5.970
Authors: James E Cummins; Jeannette Guarner; Lisa Flowers; Patricia C Guenthner; Jeanine Bartlett; Timothy Morken; Lisa A Grohskopf; Lynn Paxton; Charlene S Dezzutti Journal: Antimicrob Agents Chemother Date: 2007-03-12 Impact factor: 5.191
Authors: D I Bernstein; L R Stanberry; S Sacks; N K Ayisi; Y H Gong; J Ireland; R J Mumper; G Holan; B Matthews; T McCarthy; N Bourne Journal: Antimicrob Agents Chemother Date: 2003-12 Impact factor: 5.191
Authors: Sushama Telwatte; Katie Moore; Adam Johnson; David Tyssen; Jasminka Sterjovski; Muriel Aldunate; Paul R Gorry; Paul A Ramsland; Gareth R Lewis; Jeremy R A Paull; Secondo Sonza; Gilda Tachedjian Journal: Antiviral Res Date: 2011-04-01 Impact factor: 5.970
Authors: David Tyssen; Scott A Henderson; Adam Johnson; Jasminka Sterjovski; Katie Moore; Jennifer La; Mark Zanin; Secondo Sonza; Peter Karellas; Michael P Giannis; Guy Krippner; Steve Wesselingh; Tom McCarthy; Paul R Gorry; Paul A Ramsland; Richard Cone; Jeremy R A Paull; Gareth R Lewis; Gilda Tachedjian Journal: PLoS One Date: 2010-08-23 Impact factor: 3.240
Authors: Secondo Sonza; Adam Johnson; David Tyssen; Tim Spelman; Gareth R Lewis; Jeremy R A Paull; Gilda Tachedjian Journal: Antimicrob Agents Chemother Date: 2009-06-15 Impact factor: 5.191
Authors: Clare F Price; David Tyssen; Secondo Sonza; Ashley Davie; Sonya Evans; Gareth R Lewis; Shirley Xia; Tim Spelman; Peter Hodsman; Thomas R Moench; Andrew Humberstone; Jeremy R A Paull; Gilda Tachedjian Journal: PLoS One Date: 2011-09-15 Impact factor: 3.240